Omnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $199.37 Million

Equities analysts predict that Omnicell, Inc. (NASDAQ:OMCL) will announce $199.37 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Omnicell’s earnings. The lowest sales estimate is $198.75 million and the highest is $200.14 million. Omnicell posted sales of $182.62 million during the same quarter last year, which would indicate a positive year over year growth rate of 9.2%. The firm is scheduled to report its next quarterly earnings report on Thursday, April 25th.

According to Zacks, analysts expect that Omnicell will report full year sales of $892.30 million for the current year, with estimates ranging from $890.58 million to $894.45 million. For the next financial year, analysts anticipate that the company will post sales of $969.77 million, with estimates ranging from $936.68 million to $990.33 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Omnicell.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 7th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.16. Omnicell had a net margin of 4.79% and a return on equity of 9.31%. The business had revenue of $211.75 million during the quarter, compared to the consensus estimate of $215.41 million. During the same quarter in the prior year, the firm posted $0.55 EPS. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year.



OMCL has been the topic of several recent analyst reports. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 18th. Piper Jaffray Companies restated a “neutral” rating and set a $70.00 price objective on shares of Omnicell in a research note on Friday, February 8th. They noted that the move was a valuation call. ValuEngine upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Dougherty & Co raised their price objective on Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, March 7th. Finally, Zacks Investment Research cut Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $76.56.

NASDAQ OMCL traded down $0.75 during mid-day trading on Friday, hitting $80.96. The company’s stock had a trading volume of 4,342 shares, compared to its average volume of 303,285. Omnicell has a twelve month low of $42.01 and a twelve month high of $86.87. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.20. The company has a market cap of $3.35 billion, a P/E ratio of 52.94, a PEG ratio of 3.79 and a beta of 1.23.

In other news, EVP Nhat H. Ngo sold 1,823 shares of Omnicell stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $82.33, for a total transaction of $150,087.59. Following the sale, the executive vice president now directly owns 37,569 shares in the company, valued at approximately $3,093,055.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Peter J. Kuipers sold 1,044 shares of Omnicell stock in a transaction on Saturday, March 9th. The stock was sold at an average price of $44.34, for a total value of $46,290.96. Following the sale, the chief financial officer now owns 56,873 shares in the company, valued at $2,521,748.82. The disclosure for this sale can be found here. Insiders have sold a total of 80,772 shares of company stock worth $6,722,857 over the last quarter. Company insiders own 3.71% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc grew its holdings in shares of Omnicell by 27.9% during the third quarter. Vanguard Group Inc now owns 3,806,211 shares of the company’s stock worth $273,665,000 after purchasing an additional 830,338 shares in the last quarter. Vanguard Group Inc. lifted its position in Omnicell by 27.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,806,211 shares of the company’s stock worth $273,665,000 after buying an additional 830,338 shares during the last quarter. Norges Bank bought a new stake in Omnicell in the 4th quarter worth approximately $12,125,000. Allianz Asset Management GmbH lifted its position in Omnicell by 518.9% in the 3rd quarter. Allianz Asset Management GmbH now owns 124,170 shares of the company’s stock worth $8,928,000 after buying an additional 104,107 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in Omnicell by 45.2% in the 4th quarter. Stifel Financial Corp now owns 187,149 shares of the company’s stock worth $11,477,000 after buying an additional 58,273 shares during the last quarter. Institutional investors and hedge funds own 97.63% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Recommended Story: Penny Stocks, What You Need To Know

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.